Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 25, 393–397 (1 April 2007) | doi:10.1038/nbt0407-393
Commercializing cognitive neurotechnology|[mdash]|the ethical terrain
&
Abstract
Mental illness is one of the leading causes of disability worldwide, afflicting one in five Americans and over one in four Europeans. Cognitive neurotechnologies—technologies that enable the monitoring and/or modulation of the function of the brain—promise to improve the treatment of neurodegenerative and psychiatric disorders and may ultimately be applied to enhance emotional stability, cognitive clarity and sensory experiences.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
